325 related articles for article (PubMed ID: 21094607)
21. Exploring the chemical space around the privileged pyrazolo[3,4-d]pyrimidine scaffold: toward novel allosteric inhibitors of T315I-mutated Abl.
Vignaroli G; Mencarelli M; Sementa D; Crespan E; Kissova M; Maga G; Schenone S; Radi M; Botta M
ACS Comb Sci; 2014 Apr; 16(4):168-75. PubMed ID: 24597676
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and structure-activity relationship study of pyrazolo[3,4-d]pyrimidines as tyrosine kinase RET inhibitors.
Wang C; Liu H; Song Z; Ji Y; Xing L; Peng X; Wang X; Ai J; Geng M; Zhang A
Bioorg Med Chem Lett; 2017 Jun; 27(11):2544-2548. PubMed ID: 28404375
[TBL] [Abstract][Full Text] [Related]
23. Tetrahydro-3H-pyrazolo[4,3-a]phenanthridine-based CDK inhibitor.
Opoku-Temeng C; Dayal N; Hernandez DE; Naganna N; Sintim HO
Chem Commun (Camb); 2018 May; 54(36):4521-4524. PubMed ID: 29629444
[TBL] [Abstract][Full Text] [Related]
24. Discovery and structure - activity relationship exploration of pyrazolo[1,5-a]pyrimidine derivatives as potent FLT3-ITD inhibitors.
Chen Y; Bai G; Li Y; Ning Y; Cao S; Zhou J; Ding J; Zhang H; Xie H; Duan W
Bioorg Med Chem; 2021 Oct; 48():116422. PubMed ID: 34583130
[TBL] [Abstract][Full Text] [Related]
25. Discovery and in vitro evaluation of potent kinase inhibitors: Pyrido[1',2':1,5]pyrazolo[3,4-d]pyrimidines.
Alberti MJ; Auten EP; Lackey KE; McDonald OB; Wood ER; Preugschat F; Cutler GJ; Kane-Carson L; Liu W; Jung DK
Bioorg Med Chem Lett; 2005 Aug; 15(16):3778-81. PubMed ID: 15993060
[TBL] [Abstract][Full Text] [Related]
26. Structure-based design of novel Chk1 inhibitors: insights into hydrogen bonding and protein-ligand affinity.
Foloppe N; Fisher LM; Howes R; Kierstan P; Potter A; Robertson AG; Surgenor AE
J Med Chem; 2005 Jun; 48(13):4332-45. PubMed ID: 15974586
[TBL] [Abstract][Full Text] [Related]
27. RETRACTED: Design, synthesis, structure-activity relationship and kinase inhibitory activity of substituted 3-methyl-1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-ones.
Lamie PF
Bioorg Med Chem Lett; 2016 Jul; 26(13):3093-3097. PubMed ID: 27189674
[TBL] [Abstract][Full Text] [Related]
28. 7-Aminopyrazolo[1,5-a]pyrimidines as potent multitargeted receptor tyrosine kinase inhibitors.
Frey RR; Curtin ML; Albert DH; Glaser KB; Pease LJ; Soni NB; Bouska JJ; Reuter D; Stewart KD; Marcotte P; Bukofzer G; Li J; Davidsen SK; Michaelides MR
J Med Chem; 2008 Jul; 51(13):3777-87. PubMed ID: 18557606
[TBL] [Abstract][Full Text] [Related]
29. 1-(5-Chloro-2-alkoxyphenyl)-3-(5-cyanopyrazin-2-yl)ureas [correction of cyanopyrazi] as potent and selective inhibitors of Chk1 kinase: synthesis, preliminary SAR, and biological activities.
Wang GT; Li G; Mantei RA; Chen Z; Kovar P; Gu W; Xiao Z; Zhang H; Sham HL; Sowin T; Rosenberg SH; Lin NH
J Med Chem; 2005 May; 48(9):3118-21. PubMed ID: 15857116
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and Antibacterial Evaluation of New Pyrazolo[3,4-
Greco C; Catania R; Balacco DL; Taresco V; Musumeci F; Alexander C; Huett A; Schenone S
Molecules; 2020 Nov; 25(22):. PubMed ID: 33207806
[TBL] [Abstract][Full Text] [Related]
31. Highly potent and selective pyrazolylpyrimidines as Syk kinase inhibitors.
Choi JS; Hwang HJ; Kim SW; Lee BI; Lee J; Song HJ; Koh JS; Kim JH; Lee PH
Bioorg Med Chem Lett; 2015 Oct; 25(20):4441-6. PubMed ID: 26384287
[TBL] [Abstract][Full Text] [Related]
32. Explicit treatment of active-site waters enhances quantum mechanical/implicit solvent scoring: Inhibition of CDK2 by new pyrazolo[1,5-a]pyrimidines.
Hylsová M; Carbain B; Fanfrlík J; Musilová L; Haldar S; Köprülüoğlu C; Ajani H; Brahmkshatriya PS; Jorda R; Kryštof V; Hobza P; Echalier A; Paruch K; Lepšík M
Eur J Med Chem; 2017 Jan; 126():1118-1128. PubMed ID: 28039837
[TBL] [Abstract][Full Text] [Related]
33. Structure-based optimization of pyrazolo-pyrimidine and -pyridine inhibitors of PI3-kinase.
Staben ST; Heffron TP; Sutherlin DP; Bhat SR; Castanedo GM; Chuckowree IS; Dotson J; Folkes AJ; Friedman LS; Lee L; Lesnick J; Lewis C; Murray JM; Nonomiya J; Olivero AG; Plise E; Pang J; Prior WW; Salphati L; Rouge L; Sampath D; Tsui V; Wan NC; Wang S; Weismann C; Wu P; Zhu BY
Bioorg Med Chem Lett; 2010 Oct; 20(20):6048-51. PubMed ID: 20822905
[TBL] [Abstract][Full Text] [Related]
34. A novel pyrazolo[1,5-a]pyrimidine is a potent inhibitor of cyclin-dependent protein kinases 1, 2, and 9, which demonstrates antitumor effects in human tumor xenografts following oral administration.
Heathcote DA; Patel H; Kroll SH; Hazel P; Periyasamy M; Alikian M; Kanneganti SK; Jogalekar AS; Scheiper B; Barbazanges M; Blum A; Brackow J; Siwicka A; Pace RD; Fuchter MJ; Snyder JP; Liotta DC; Freemont PS; Aboagye EO; Coombes RC; Barrett AG; Ali S
J Med Chem; 2010 Dec; 53(24):8508-22. PubMed ID: 21080703
[TBL] [Abstract][Full Text] [Related]
35. 5-Substituted 3-isopropyl-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidines with anti-proliferative activity as potent and selective inhibitors of cyclin-dependent kinases.
Vymětalová L; Havlíček L; Šturc A; Skrášková Z; Jorda R; Pospíšil T; Strnad M; Kryštof V
Eur J Med Chem; 2016 Mar; 110():291-301. PubMed ID: 26851505
[TBL] [Abstract][Full Text] [Related]
36. Potent and selective pyrazolo[1,5-a]pyrimidine based inhibitors of B-Raf(V600E) kinase with favorable physicochemical and pharmacokinetic properties.
Ren L; Laird ER; Buckmelter AJ; Dinkel V; Gloor SL; Grina J; Newhouse B; Rasor K; Hastings G; Gradl SN; Rudolph J
Bioorg Med Chem Lett; 2012 Jan; 22(2):1165-8. PubMed ID: 22196124
[TBL] [Abstract][Full Text] [Related]
37. Pyrimidine-based pyrazoles as cyclin-dependent kinase 2 inhibitors: Design, synthesis, and biological evaluation.
Vekariya MK; Vekariya RH; Brahmkshatriya PS; Shah NK
Chem Biol Drug Des; 2018 Sep; 92(3):1683-1691. PubMed ID: 29767460
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and SAR of 4-(pyrazol-3-yl)-pyridines as novel c-jun N-terminal kinase inhibitors.
Noël R; Shin Y; Song X; He Y; Koenig M; Chen W; Ling YY; Lin L; Ruiz CH; LoGrasso P; Cameron MD; Duckett DR; Kamenecka TM
Bioorg Med Chem Lett; 2011 May; 21(9):2732-5. PubMed ID: 21185177
[TBL] [Abstract][Full Text] [Related]
39. Pyrazolo[4,3-d]pyrimidine bioisostere of roscovitine: evaluation of a novel selective inhibitor of cyclin-dependent kinases with antiproliferative activity.
Jorda R; Havlícek L; McNae IW; Walkinshaw MD; Voller J; Sturc A; Navrátilová J; Kuzma M; Mistrík M; Bártek J; Strnad M; Krystof V
J Med Chem; 2011 Apr; 54(8):2980-93. PubMed ID: 21417417
[TBL] [Abstract][Full Text] [Related]
40. Optimization of a pyrazoloquinolinone class of Chk1 kinase inhibitors.
Brnardic EJ; Garbaccio RM; Fraley ME; Tasber ES; Steen JT; Arrington KL; Dudkin VY; Hartman GD; Stirdivant SM; Drakas BA; Rickert K; Walsh ES; Hamilton K; Buser CA; Hardwick J; Tao W; Beck SC; Mao X; Lobell RB; Sepp-Lorenzino L; Yan Y; Ikuta M; Munshi SK; Kuo LC; Kreatsoulas C
Bioorg Med Chem Lett; 2007 Nov; 17(21):5989-94. PubMed ID: 17804227
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
